An interventional study of Human recombinant growth hormone in Osteoporosis Pseudoglioma Syndrome, sponsored by University of Maryland, Baltimore. Withdrawn at 1 site in United States. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2022-04-08.
Sponsored by University of Maryland, Baltimore · Not applicable, Interventional, and Treatment
Osteoporosis pseudoglioma (OPPG) syndrome is a rare autosomal recessive condition of childhood osteoporosis and congenital blindness for which new treatments are needed. We have found that body fat is increased in OPPG and muscle mass is reduced. We hypothesize that growth hormone therapy will improve muscle mass and bone strength in OPPG.
Osteoporosis pseudoglioma (OPPG) syndrome is a rare autosomal recessive condition of childhood osteoporosis and congenital blindness for which new treatments are needed. We have found that body fat is increased in OPPG and muscle mass is reduced. We hypothesize that growth hormone therapy will improve muscle mass and bone strength in OPPG.
1,640 studies on the registry are indexed under Osteoporosis; 212 are open to participants now.
Browse Osteoporosis studies →University of Maryland, Baltimore is the lead sponsor of 687 studies on the registry; 130 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 63 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Growth hormone treatment for 6 months
Biological: Human recombinant growth hormone
growth hormone treatment for 6 months (daily, weight based)
Bone quality by pQCT
By pQCT: periosteal circumference, cortical density, trabecular density, section modulus
Time frame: 6 months
Body fat percent
Percent body fat by DXA
Time frame: 6 months
This study is withdrawn, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Maryland, Baltimore